Joining the DoTS: new approach to classifying adverse drug reactions
about
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and childrenNeuraminidase inhibitors for preventing and treating influenza in healthy adults and children - a review of clinical study reportsCommunicating with patients about harms and risksDilemmas of the causality assessment tools in the diagnosis of adverse drug reactionsAntibiotics and allergic disorders in childhoodAn agenda for research on adverse drug reactionsAdverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodesApproaches to recording drug allergies in electronic health records: qualitative studyComprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources.Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin.Laughter and MIRTH (Methodical Investigation of Risibility, Therapeutic and Harmful): narrative synthesis.A case of toxic epidermal necrolysis caused by trimethoprim-sulfamethoxazole.Monitoring in chronic disease: a rational approach.A manifesto for clinical pharmacology from principles to practiceOculomotor nerve palsy associated with bortezomib in a patient with multiple myeloma: a case report.The quality of information on monitoring for haematological adverse drug reactions.Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine.Communicating information about drug safety.Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series.Assessing the benefit-harm balance at the bedside.Detection, verification, and quantification of adverse drug reactionsGenetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study.Pattern of Adverse Drug Reactions in Children Attending the Department of Pediatrics in a Tertiary Care Center: A Prospective Observational Study.Adverse drug reactions--no farewell to harms.Should we tolerate tolerability as an objective in early drug development?Monitoring drug therapy.PharmacovigilanceReview article: Acute serious and fatal reactions to contrast media: our current understanding.Monitoring for adverse drug reactions.Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skinPost-mortem clinical pharmacology.Medication errors: problems and recommendations from a consensus meeting.Comparison of study designs used to detect and characterize pharmacogenomic interactions in nonexperimental studies: a simulation study.Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority.Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?Adverse drug reactions in dermatology.Advances in the Pharmacogenomics of Adverse Drug Reactions.Causality Assessment in Pharmacovigilance: Still a Challenge.Bisphosphonate therapy start may transiently increase the risk of tendon rupture in patients with glucocorticoid co-medication: a population-based observational study.
P2860
Q24203905-87DC8AED-6F63-4157-991A-23605B04488CQ24235164-7267A1BB-6DFB-4656-9EBE-C7D1DF00C68DQ24794450-88C6E9C2-91A5-4563-9759-2F1DD7F43D70Q26743858-63432A77-5342-4CC8-BADE-3E87FBF8F2D7Q28386230-C1535F75-4C5C-41E6-B220-72E5771DA053Q28469318-395D5CEA-57F1-4AFF-BB4E-E0CE7DD48917Q28474740-5F8431D9-31D3-4BF9-9243-B95C0D9EB356Q28537940-EAFB620F-71E7-4984-9BB9-27FECA745E39Q30840099-B96E766D-F671-47A0-A2E8-66C69EA52B4BQ30994474-BD518591-61F0-4479-9800-0DDA27EFD538Q31060847-14F0096B-2795-41F9-A57C-CD388C59E7F4Q33163620-40ADC71A-10D6-4D66-958D-34F8D758C4E9Q33879666-B3340A0F-5366-4AB7-99A0-19694001FD16Q33932916-AB0D09E9-ECC4-4171-8C39-990BD32A9607Q34019310-BF63D512-DA97-4ED8-BE31-FFA566936E1FQ34321781-479C8362-1405-4D63-B623-4224A6960230Q34454377-0A16EFD0-0AD1-4752-872A-6A73A0634F5AQ34623044-5116595A-FB12-4ABC-8557-92C6311CF9AEQ34770553-108AAB85-5E13-4416-A94A-F7B7484F74AAQ35135876-4786C567-F2E4-4148-9FD3-F7892A66F7AAQ35614664-38CF23DD-6078-4C0F-A2DC-52E044F513B5Q35615527-6864EFD7-D06A-41C5-80D5-A55834555B66Q35863499-B0B61736-6AB0-4DBB-A4F6-1948AF6291E1Q35944963-243E17E4-BEF9-4BC1-9814-656CA567759CQ36024353-8B6E9C3D-8FBD-4839-8C10-BE7E7539F79BQ36024658-20C7C9F2-FFFC-4C07-98CB-884357C70C2EQ36081472-7AF23AF2-E1DE-4F0E-B4F0-603EC0C73639Q36081511-3DA9CCF9-969C-4E78-BC54-C888E2FF5650Q36208379-5BC86FC1-87E2-47B8-82F6-9253DCD8FA29Q36423153-C0E0D21B-A2CC-4298-9996-C1BEE5814CF3Q36440366-9D03FADE-D127-48D2-8FD0-5F7291CC7B88Q36922235-4AD0E79B-BD2A-4892-B4D3-FDA28047F389Q37295589-B43DAE35-6ED2-4346-90E1-CE8CA9031D26Q37624739-BEDC93B9-75AF-4FFE-BFB6-FC95A92E8B54Q38036926-9775208C-D354-48F5-BC64-8E5BB54480A7Q38078815-CF41C937-F663-4C6E-B0D7-B77B3B10616BQ38333021-CC456804-24DF-4F80-AD74-A8D8DF603FE9Q38663764-A38FBCE6-1D7D-47F7-BE90-5B08DBCF88A1Q38936372-EC5FEF46-AC1F-4A50-8BCD-28BA37B7170CQ39686596-57689DFB-F4D2-44E9-B4F6-CE2315DBD323
P2860
Joining the DoTS: new approach to classifying adverse drug reactions
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Joining the DoTS: new approach to classifying adverse drug reactions
@ast
Joining the DoTS: new approach to classifying adverse drug reactions
@en
type
label
Joining the DoTS: new approach to classifying adverse drug reactions
@ast
Joining the DoTS: new approach to classifying adverse drug reactions
@en
prefLabel
Joining the DoTS: new approach to classifying adverse drug reactions
@ast
Joining the DoTS: new approach to classifying adverse drug reactions
@en
P2860
P1433
P1476
Joining the DoTS: new approach to classifying adverse drug reactions
@en
P2093
J K Aronson
P2860
P304
P356
10.1136/BMJ.327.7425.1222
P407
P50
P577
2003-11-01T00:00:00Z